drugset / Trial / NCT03363659

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

NCT03363659

Phase 2 Terminated 15 enrolled Wake Forest University Health Sciences
NaSingle-groupOpen-labelTreatment

Summary

One of Disulfiram antitumor effects suggested in preclinical studies is MGMT (methyl-guanine-methyl-transferase) inhibition. Disulfiram MGMT inhibitory effect is enhanced by addition of Copper. This study evaluates the impact of Disulfiram (DSF) + Copper (Cu) combination when added to standard Temozolomide in the treatment of unmethylated Glioblastoma Multiforme (GBM) patients.

Timeline

Start
2018-03-28
Primary completion
2022-01-13
Completion
2022-01-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Disulfiram Small molecule 125 mg Oral
Background Temozolomide Small molecule 150 mg/m2 Oral

Indications